Linvoseltamab治疗复发/难治性多发性骨髓瘤
这项I/II期首次人体试验评估了linvoseltamab(BCMA×CD3双特异性抗体)50 mg和200 mg剂量治疗复发/难治性多发性骨髓瘤的安全性和疗效。200 mg组117例患者ORR为71%,≥CR为50%,中位DOR为29.4个月(95% CI,19.2至不可评估),安全性可接受。
要点
- 200 mg组117例RRMM患者ORR 71%,≥CR 50%,中位DOR 29.4个月(95% CI,19.2至不可评估)。
- 50 mg组104例患者ORR 48%,≥CR 21%,中位随访7.4个月。
- 200 mg组常见不良事件包括细胞因子释放综合征、中性粒细胞减少和贫血,感染发生率为74.4%。
核心结论
- Linvoseltamab 200 mg在复发/难治性多发性骨髓瘤患者中诱导深度且持久的缓解,中位DOR为29.4个月,安全性可接受。
研究设计与样本
- I/II期首次人体试验,评估linvoseltamab(BCMA×CD3双特异性抗体)50 mg和200 mg剂量治疗复发/难治性多发性骨髓瘤。
- II期入组患者为复发/难治性多发性骨髓瘤,既往≥三线治疗(包括蛋白酶体抑制剂、免疫调节药物和抗CD38抗体)后进展,或为三类药物难治。
- II期治疗方案为每周一次至第14周,之后每2周一次;200 mg组在第24周达到≥非常好的部分缓解的患者改为每4周一次。
- II期主要终点为总缓解率(ORR)。
主要发现
- 200 mg组117例患者中位年龄70岁,39%具有高危细胞遗传学,28%为五药难治;中位随访14.3个月,ORR为71%,≥完全缓解(CR)为50%。
- 50 mg组104例患者中位随访7.4个月,ORR为48%,≥CR为21%。
- 200 mg组缓解患者(n=83)中位缓解持续时间(DOR)为29.4个月(95% CI,19.2至不可评估)。
- 200 mg组常见不良事件包括细胞因子释放综合征(35.0% 1级,10.3% 2级,0.9% 3级)、中性粒细胞减少(0.9% 2级,18.8% 3级,23.1% 4级)和贫血(3.4% 1级,4.3% 2级,30.8% 3级)。
- 免疫效应细胞相关神经毒性综合征发生于7.7%的患者(1级、2级、3级各2.6%);感染发生率为74.4%(33.3% 3级,2.6% 4级),感染频率和严重程度随时间下降。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody in relapsed/refractory multiple myeloma (RRMM). METHODS: Phase II eligible patients had RRMM that either progressed on/after ≥three lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody or was triple-class (PI/IMiD/anti-CD38) refractory. Phase II treatment was once a week through week 14 and then once every 2 weeks. Phase II 200 mg patients who achieved a ≥very good partial response by week 24 received linvoseltamab once every 4 weeks. The primary end point in phase II was overall response rate (ORR). RESULTS: Among the 117 patients treated with 200 mg, the median age was 70 years, 39% had high-risk cytogenetics, and 28% had penta-refractory disease. At a median follow-up of 14.3 months, the ORR was 71%, with 50% achieving ≥complete response (CR). In 104 patients treated with 50 mg at a median follow-up of 7.4 months, the ORR was 48%, with 21% achieving ≥CR. The median duration of response (DOR) for 200 mg patients (n = 83) was 29.4 months (95% CI, 19.2 to not evaluable). Among 200 mg patients, the most common adverse events included cytokine release syndrome (35.0% Gr1, 10.3% Gr2, 0.9% Gr3), neutropenia (0.9% Gr2, 18.8% Gr3, 23.1% Gr4), and anemia (3.4% Gr1, 4.3% Gr2, 30.8% Gr3). Immune effector cell-associated neurotoxicity syndrome occurred in 7.7% of patients (2.6% each Gr1, Gr2, Gr3). Infections were reported in 74.4% of patients (33.3% Gr3, 2.6% Gr4); infection frequency and severity declined over time. CONCLUSION: Linvoseltamab 200 mg induced deep and durable responses, with a median DOR of 29.4 months, in patients with RRMM with an acceptable safety profile.
引用
- Bumma N, Richter J, Jagannath S, et al. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2024. PMID: 38879802. doi:10.1200/JCO.24.01008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。